Ovarian Cancer | Clinical

Rucaparib Improves PFS in Patent With BRCA Mutation-Positive Relapsed Ovarian Cancer

December 21, 2020

Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.

Olaparib Shows PFS Benefit at 5-Year Follow-Up in BRCA Ovarian Cancer

September 18, 2020

Patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who experienced complete or partial response following platinum-based chemotherapy continued to exhibit benefit in progression-free survival when receiving olaparib at long-term follow up versus placebo as first-line maintenance.

Atezolizumab Plus Bevacizumab and Chemotherapy Falls Short of PFS Improvement in Phase 3 Ovarian Cancer Trial

July 13, 2020

The phase 3 IMagyn500 clinical trial failed to meet its primary end point of progression-free survival with the addition of atezolizumab to bevacizumab plus paclitaxel and carboplatin chemotherapy in patients with newly diagnosed advanced ovarian cancer.